Journal of Clinical Oncology
Articles in this Issue
Development of skin-integrated melanoma organoids to study the tumor microenvironment-mediated mechanisms of melanoma progression and metastasis in vitro.
e21547 Background: Resistance to targeted therapies remains a challenge in metastatic melanoma. The tumor microenvironment (TME) influences cancer progres...
Neoadjuvant transhepatic arterial infusion chemotherapy (HAIC) with FOLFOX regime plus cadonilimab (PD-1/CTLA-4 bispecific antibody) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (CAR_Hero study).
4139 Background: The recurrence rate of hepatocellular carcinoma (HCC) remains high, with multinodular HCC being a well-de...
Impact of targeted therapies (TT) and immunotherapy (IO) on outcomes in patients (pts) with anaplastic thyroid carcinoma (ATC): International data from the Spanish GETNE registry.
e18154 Background: The systemic treatment landscape in ATC is rapidly evolving, with promising therapies such as BRAF-targeted therapy (TT) and immunother...
Efficacy of immune checkpoint inhibitors (ICIs) in advanced large cell neuroendocrine carcinoma (LCNEC) of the lung: A systematic review and meta-analysis.
8576 Background: LCNEC of the lung is a high-grade neuroendocrine carcinoma with characteristics of both small cell lung cancer (SCLC) and non-small cell...
Retrospective study of unresectable stage III or stage IV melanoma refractory to immune checkpoint and BRAF/MEK inhibitors, treated with triplet vs doublet therapy: A single institution experience.
e21500 Background: The incidence of melanoma has been increasing in the last decade. Advanced malignant melanoma (unresectable stage III or stage IV melan...
Real world evidence on effectiveness of palbociclib in Indian patients with breast cancer: A single centre, investigator-initiated, retrospective study.
e13054 Background: Cyclin dependent kinase 4/6 inhibitors in combination with endocrine therapy are the standard of care in patients with hormone receptor...
Long-term safety of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC): 7-year follow-up from the largest global prospective study.
5048 Background: Ra-223, an alpha-emitting radionuclide, is the first agent of its kind approved for the treatment of mCRPC. Although a pivotal phase 3 st...
Impact of health literacy in cancer outpatients receiving oral anticancer drugs and followed by the ONCORAL multidisciplinary city-hospital educational follow-up: The LITTORAL study.
12127 Background: Multidisciplinary follow-up is crucial to manage drug-related problems (DRP) associated with oral anticancer therapies (OAT). However, t...
The efficacy and safety of eutideron, etoposide, and bevacizumab in patients with brain metastases from breast cancer.
TPS1135 Background: Brain metastases (BM) from breast cancer (BC) are a significant therapeutic challenge, with limited systemic treatment options capable...
Neurologic adverse effects associated with the use of T-cell engager therapy in multiple myeloma: Insights from FAERS database.
e19502 Background: Multiple myeloma (MM) is an incurable malignancy characterized by the clonal proliferation of plasma cells, with relapse/refractory MM...
Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor–positive breast cancer: Results from the ASTRRA trial.
506 Background: The ASTRRA trial previously demonstrated that adding ovarian function suppression (OFS) to tamoxifen (TAM)...
Clinical factors associated with surgical resection rate and survival prognosis after conversion therapy with HAIC combined with targeted and immunotherapy for unresectable hepatocellular carcinoma.
e16211 Background: Hepatic artery infusion chemotherapy (HAIC) combined with targeted and immunotherapy is currently one of the main treatment strategies...
Disparities in cachexia and anorexia in hospitalized female patients with breast cancer: A national population-based study.
12097 Background: Breast cancer is the most common cancer in females in the US. Cachexia and anorexia are common complications from either the disease its...
A minimal comprehensive somatic panel to aid clinical decision making in a low cost setting.
3141 Background: Large next-generation sequencing (NGS) panels (> 300 genes) offer multiple potential therapeutic options for patients with metastatic...
Comparing the use and quality of palliative and end-of-life care between Asian and non-Asian patients with cancer.
e13765 Background: Palliative care (PC) is associated with improved outcomes in patients with cancer. The term Asian-American refers to various cultures a...
Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ <i>EGFR</i> wildtype ( <i>EGFR</i> wt) non-squamous non-small cell lung cancer (NSCLC) patients (pts) with c-Met overexpression (OE).
3027 Background: Teliso-V is an antibody-drug conjugate comprising the c-Met–targeting antibody telisotuzumab linked to the microtubule inhibitor monometh...
Tumor-derived ILT5 and suppression of T cell immunity in non-small cell lung cancer.
8531 Background: Immune checkpoint inhibitors targeting PD-(L)1 pathways have revolutionized the treatment of non-small cell lung cancer (NSCLC) since las...
Real-world analysis of factors influencing turnaround time (TAT) for tissue comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC).
11161 Background: CGP is an integral part of the standard of care for many solid tumor malignancies, and especially for NSCLC, as testing informs first-li...
Facilitating precision medicine in the community oncology setting: Artificial intelligence clinical decision support and expert consultation combined in a demonstration project.
e13693 Background: More than 75% of cancer patients are treated in the community oncology setting. Data show that the majority of patients (~70%) eligible...
Correlation between computational insights into non-coding RNA regulatory networks and glioblastoma survival.
e14028 Background: Glioblastoma (GBM) is a highly aggressive primary brain tumor with poor prognosis and limited therapeutic options. Emerging evidence hi...
SARS-CoV-2 infection risk and COVID-19 prevalence in cancer patients during the first wave of COVID-19 pandemic in a northernItaly virus epicenter area.
e22560 Background: The COVID-19 pandemic significantly impacted cancer patients, who are more vulnerable to severe outcomes. This study examines the risk...
Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405.
3128 Background: LncRNAs have emerged as key regulators of cancer progression and therapeutic responses. In CRC, several lncRNAs have been implicated in m...
Association of immune cell subsets and cytokine profiles with immune-related hyperinflammatory states after CAR T-cell therapy.
e19008 Background: Cytokine release syndrome (CRS) is typically reversible in CAR-T therapy, while hyperinflammatory syndromes like macrophage activation-...
A multicenter, randomized, controlled, open-label, phase 2 study of the PD-1/IL-2 <sup>α-bias</sup> bispecific antibody fusion protein IBI363 in mucosal and acral melanoma.
TPS9594 Background: Although several immune checkpoint inhibitors have been approved for advanced melanoma, there remain significant unmet clinical needs,...
Adaptive designed eniluracil + capecitabine phase 2 trial in advanced or metastatic breast cancer patients.
TPS1133 Background: Ethynyl-uracil (eniluracil or 6422), an irreversible inhibitor of the dihydropyrimidine dehydrogenase enzyme that metabolizes 5-FU to...